9. REFERENCES
1.Patrikidou, A., et al. European Association of Urology Guidelines on Testicular Cancer: 2023 Update. Eur Urol, 2023. 84: 289.
https://www.ncbi.nlm.nih.gov/pubmed/37183161
2.Guyatt, G.H., et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. Bmj, 2008. 336: 924.
https://pubmed.ncbi.nlm.nih.gov/18436948/
3.National Comprehensive Cancer Network. Testicular Cancer (Version 1.2026).
https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1468
4.Phillips, B. Oxford Centre for Evidence-based Medicine Levels of Evidence. Updated by Jeremy Howick March 2009. 1998.
https://www.cebm.ox.ac.uk/resources/levels-of-evidence/oxford-centre-for-evidence-based-medicine-levels-of-evidence-march-2009
5.Guyatt, G.H., et al. Going from evidence to recommendations. BMJ, 2008. 336: 1049.
https://www.ncbi.nlm.nih.gov/pubmed/18467413
6.Park, J.S., et al. Recent global trends in testicular cancer incidence and mortality. Medicine (Baltimore), 2018. 97: e12390.
https://www.ncbi.nlm.nih.gov/pubmed/30213007
7.Nigam, M., et al. Increasing incidence of testicular cancer in the United States and Europe between 1992 and 2009. World J Urol, 2015. 33: 623.
https://www.ncbi.nlm.nih.gov/pubmed/25030752
8.Gurney, J.K., et al. International Trends in the Incidence of Testicular Cancer: Lessons from 35 Years and 41 Countries. Eur Urol, 2019. 76: 615.
https://www.ncbi.nlm.nih.gov/pubmed/31324498
9.Huang, J., et al. Worldwide Distribution, Risk Factors, and Temporal Trends of Testicular Cancer Incidence and Mortality: A Global Analysis. Eur Urol Oncol, 2022. 5: 566.
https://www.ncbi.nlm.nih.gov/pubmed/35863988
10.Znaor, A., et al. Global patterns in testicular cancer incidence and mortality in 2020. Int J Cancer, 2022. 151: 692.
https://www.ncbi.nlm.nih.gov/pubmed/35277970
11.Oosterhuis, J.W., et al. Testicular germ-cell tumours in a broader perspective. Nat Rev Cancer, 2005. 5: 210.
https://www.ncbi.nlm.nih.gov/pubmed/15738984
12.Looijenga, L.H.J., et al. Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers: IV: Current and Future Utilization of Molecular-Genetic Tests for Testicular Germ Cell Tumors. Am J Surg Pathol, 2020. 44: e66.
https://www.ncbi.nlm.nih.gov/pubmed/32205480
13.Jorgensen, N., et al. Testicular dysgenesis syndrome comprises some but not all cases of hypospadias and impaired spermatogenesis. Int J Androl, 2010. 33: 298.
https://www.ncbi.nlm.nih.gov/pubmed/20132348
14.Lip, S.Z., et al. A meta-analysis of the risk of boys with isolated cryptorchidism developing testicular cancer in later life. Arch Dis Child, 2013. 98: 20.
https://www.ncbi.nlm.nih.gov/pubmed/23193201
15.Del Giudice, F., et al. Association between male infertility and male-specific malignancies: systematic review and meta-analysis of population-based retrospective cohort studies. Fertil Steril, 2020. 114: 984.
https://www.ncbi.nlm.nih.gov/pubmed/32709378
16.Slowikowska-Hilczer, J., et al. Risk of gonadal neoplasia in patients with disorders/differences of sex development. Cancer Epidemiol, 2020. 69: 101800.
https://www.ncbi.nlm.nih.gov/pubmed/32905884
17.Mostert, M.M., et al. Comparative genomic hybridization of germ cell tumors of the adult testis: confirmation of karyotypic findings and identification of a 12p-amplicon. Cancer Genet Cytogenet, 1996. 89: 146.
https://www.ncbi.nlm.nih.gov/pubmed/8697422
18.Bosl, G.J., et al. Testicular germ-cell cancer. N Engl J Med, 1997. 337: 242.
https://www.ncbi.nlm.nih.gov/pubmed/9227931
19.Greene, M.H., et al. Familial testicular germ cell tumors in adults: 2010 summary of genetic risk factors and clinical phenotype. Endocr Relat Cancer, 2010. 17: R109.
https://www.ncbi.nlm.nih.gov/pubmed/20228134
20.Lutke Holzik, M.F., et al. Genetic predisposition to testicular germ-cell tumours. Lancet Oncol, 2004. 5: 363.
https://www.ncbi.nlm.nih.gov/pubmed/15172357
21.Kharazmi, E., et al. Cancer Risk in Relatives of Testicular Cancer Patients by Histology Type and Age at Diagnosis: A Joint Study from Five Nordic Countries. Eur Urol, 2015. 68: 283.
https://www.ncbi.nlm.nih.gov/pubmed/25913387
22.Schaapveld, M., et al. Risk and prognostic significance of metachronous contralateral testicular germ cell tumours. Br J Cancer, 2012. 107: 1637.
https://www.ncbi.nlm.nih.gov/pubmed/23059747
23.Peng, X., et al. The association risk of male subfertility and testicular cancer: a systematic review. PLoS One, 2009. 4: e5591.
https://www.ncbi.nlm.nih.gov/pubmed/19440348
24.Seikkula, H., et al. Familial aggregation of testicular cancer among early-onset cancer survivors. A prospective observational cohort data from Finland. Cancer Epidemiol, 2020. 69: 101807.
https://www.ncbi.nlm.nih.gov/pubmed/33045472
25.Maroto, P., et al. Incidence and clinical pattern of contralateral synchronous and metachronous germ cell testicular cancer. Urol Oncol, 2021. 39: 135 e17.
https://www.ncbi.nlm.nih.gov/pubmed/33189529
26.Blok, J.M., et al. Dose-Dependent Effect of Platinum-Based Chemotherapy on the Risk of Metachronous Contralateral Testicular Cancer. J Clin Oncol, 2021. 39: 319.
https://www.ncbi.nlm.nih.gov/pubmed/33119475
27.Hellesnes, R., et al. Metachronous Contralateral Testicular Cancer in the Cisplatin Era: A Population-Based Cohort Study. J Clin Oncol, 2021. 39: 308.
https://www.ncbi.nlm.nih.gov/pubmed/33356420
28.Pluta, J., et al. Identification of 22 susceptibility loci associated with testicular germ cell tumors. Nat Commun, 2021. 12: 4487.
https://www.ncbi.nlm.nih.gov/pubmed/34301922
29.Moch, H., et al. The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. Eur Urol, 2022. 82: 458.
https://www.ncbi.nlm.nih.gov/pubmed/35853783
30.Lobo, J., et al. Expert Genitourinary Pathology Review of Orchiectomy Specimens Should Be Mandatory for Optimal Management. Recommendations from the European Association of Urology Guidelines Panel on Testicular Cancer. Eur Urol, 2025.
https://pubmed.ncbi.nlm.nih.gov/41344929/
31.James D. Brierley, et al., The TNM Classification of Malignant Tumours 9th edition. 2025.
https://www.uicc.org/news-and-updates/25-7-announcements/9th-edition-uicc-tnm-classification-malignant-tumours-now-available
32.Amin, M.B., et al., AJCC Cancer Staging Manual. 8th ed. AJCC Cancer Staging Manual. 2017.
https://www.springer.com/la/book/9783319406176
33.Klepp, O., et al. Early clinical stages (CS1, CS1Mk+ and CS2A) of non-seminomatous testis cancer. Value of pre- and post-orchiectomy serum tumor marker information in prediction of retroperitoneal lymph node metastases. Swedish-Norwegian Testicular Cancer Project (SWENOTECA). Ann Oncol, 1990. 1: 281.
https://www.ncbi.nlm.nih.gov/pubmed/1702312
34.Verhoeven, R.H., et al. Markedly increased incidence and improved survival of testicular cancer in the Netherlands. Acta Oncol, 2014. 53: 342.
https://www.ncbi.nlm.nih.gov/pubmed/23992111
35.Boormans, J.L., et al. Testicular Tumour Size and Rete Testis Invasion as Prognostic Factors for the Risk of Relapse of Clinical Stage I Seminoma Testis Patients Under Surveillance: a Systematic Review by the Testicular Cancer Guidelines Panel. Eur Urol, 2018. 73: 394.
https://www.ncbi.nlm.nih.gov/pubmed/29100813
36.Zengerling, F., et al. Prognostic factors for tumor recurrence in patients with clinical stage I seminoma undergoing surveillance-A systematic review. Urol Oncol, 2018. 36: 448.
https://www.ncbi.nlm.nih.gov/pubmed/28712790
37.Boormans, J.L., et al. Prognostic Factor Risk Groups for Clinical Stage I Seminoma: An Individual Patient Data Analysis by the European Association of Urology Testicular Cancer Guidelines Panel and Guidelines Office. Eur Urol Oncol, 2024. 7: 537.
https://pubmed.ncbi.nlm.nih.gov/37951820/
38.Wagner, T., et al. Prognostic Factors for Relapse in Patients With Clinical Stage I Testicular Seminoma: A Nationwide, Population-Based Cohort Study. J Clin Oncol, 2024. 42: 81.
https://pubmed.ncbi.nlm.nih.gov/37683134/
39.Wagner, T., et al. Prognostic factors for relapse in patients with clinical stage I testicular non-seminoma: A nationwide, population-based cohort study. Eur J Cancer, 2024. 202: 114025.
https://pubmed.ncbi.nlm.nih.gov/38531266/
40.Beyer, J., et al. Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium. J Clin Oncol, 2021. 39: 1553.
https://www.ncbi.nlm.nih.gov/pubmed/33729863
41.Germa-Lluch, J.R., et al. Clinical pattern and therapeutic results achieved in 1490 patients with germ-cell tumours of the testis: the experience of the Spanish Germ-Cell Cancer Group (GG). Eur Urol, 2002. 42: 553.
https://www.ncbi.nlm.nih.gov/pubmed/12477650
42.Angulo, J.C., et al. Clinicopathological study of regressed testicular tumors (apparent extragonadal germ cell neoplasms). J Urol, 2009. 182: 2303.
https://www.ncbi.nlm.nih.gov/pubmed/19762049
43.Mead, G.M., et al. The International Germ Cell Consensus Classification: a new prognostic factor-based staging classification for metastatic germ cell tumours. Clin Oncol (R Coll Radiol), 1997. 9: 207.
https://www.ncbi.nlm.nih.gov/pubmed/9315391
44.Gillessen, S., et al. Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium. J Clin Oncol, 2021. 39: 1563.
https://www.ncbi.nlm.nih.gov/pubmed/33822655
45.Ager, M., et al. Radiological features characterising indeterminate testes masses: a systematic review and meta-analysis. BJU Int, 2023. 131: 288.
https://www.ncbi.nlm.nih.gov/pubmed/35980855
46.Chavarriaga, J., et al. Small Testicular Masses: Contemporary Diagnostic and Treatment Strategies, Future Directions, and Knowledge Gaps. Urol Oncol, 2023. 41: 331.
https://www.ncbi.nlm.nih.gov/pubmed/36990940
47.Henriques, D., et al. Prevalence and Management of Incidental Testicular Masses-A Systematic Review. J Clin Med, 2022. 11: 5770.
https://www.ncbi.nlm.nih.gov/pubmed/36233639
48.Tsili, A.C., et al. When to ask for an MRI of the scrotum. Andrology, 2021. 9: 1395.
https://www.ncbi.nlm.nih.gov/pubmed/33964115
49.de Wit, M., et al. [18F]-FDG-PET in clinical stage I/II non-seminomatous germ cell tumours: results of the German multicentre trial. Ann Oncol, 2008. 19: 1619.
https://www.ncbi.nlm.nih.gov/pubmed/18453520
50.Huddart, R.A., et al. 18fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high-risk, clinical stage I nonseminomatous germ cell tumors: preliminary report of MRC Trial TE22--the NCRI Testis Tumour Clinical Study Group. J Clin Oncol, 2007. 25: 3090.
https://www.ncbi.nlm.nih.gov/pubmed/17634488
51.Busch, J., et al. Can magnetic resonance imaging replace conventional computerized tomography for follow-up of patients with testicular cancer? A systematic review. World J Urol, 2022. 40: 2843.
https://www.ncbi.nlm.nih.gov/pubmed/35037965
52.Smith-Bindman, R., et al. Medical Imaging and Pediatric and Adolescent Hematologic Cancer Risk. N Engl J Med, 2025. 393: 1269.
https://pubmed.ncbi.nlm.nih.gov/40961449/
53.Pasoglou, V., et al. Whole Body MRI in the Detection of Lymph Node Metastases in Patients with Testicular Germ Cell Cancer. Life (Basel), 2022. 12.
https://www.ncbi.nlm.nih.gov/pubmed/35207499
54.Feldman, D.R., et al. Brain Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Options--An Analysis From the Global Germ Cell Cancer Group. J Clin Oncol, 2016. 34: 345.
https://www.ncbi.nlm.nih.gov/pubmed/26460295
55.Sutcliffe, P., et al. A systematic review of evidence on malignant spinal metastases: natural history and technologies for identifying patients at high risk of vertebral fracture and spinal cord compression. Health Technol Assess, 2013. 17: 1.
https://www.ncbi.nlm.nih.gov/pubmed/24070110
56.Kaufmann, T.J., et al. Consensus recommendations for a standardized brain tumor imaging protocol for clinical trials in brain metastases. Neuro Oncol, 2020. 22: 757.
https://www.ncbi.nlm.nih.gov/pubmed/32048719
57.Dieckmann, K.P., et al. Serum Tumour Markers in Testicular Germ Cell Tumours: Frequencies of Elevated Levels and Extents of Marker Elevation Are Significantly Associated with Clinical Parameters and with Response to Treatment. Biomed Res Int, 2019. 2019: 5030349.
https://www.ncbi.nlm.nih.gov/pubmed/31275973
58.Nicholson, B.D., et al. The diagnostic performance of current tumour markers in surveillance for recurrent testicular cancer: A diagnostic test accuracy systematic review. Cancer Epidemiol, 2019. 59: 15.
https://www.ncbi.nlm.nih.gov/pubmed/30658216
59.Dieckmann, K.P., et al. Associations of serum levels of microRNA-371a-3p (M371) with risk factors for progression in nonseminomatous testicular germ cell tumours clinical stage 1. World J Urol, 2022. 40: 317.
https://www.ncbi.nlm.nih.gov/pubmed/34775512
60.Leao, R., et al. Circulating MicroRNAs, the Next-Generation Serum Biomarkers in Testicular Germ Cell Tumours: A Systematic Review. Eur Urol, 2021. 80: 456.
https://www.ncbi.nlm.nih.gov/pubmed/34175151
61.Belge, G., et al. Serum levels of microRNA-371a-3p are not elevated in testicular tumours of non-germ cell origin. J Cancer Res Clin Oncol, 2021. 147: 435.
https://www.ncbi.nlm.nih.gov/pubmed/33200255
62.Lafin, J., et al. Refining the serum miR-371a-3p test for viable germ cell tumor detection: identification and definition of an indeterminate range. Res Sq, 2023.
https://www.ncbi.nlm.nih.gov/pubmed/36993198
63.Patel, H.D., et al. Testis-sparing surgery and scrotal violation for testicular masses suspicious for malignancy: A systematic review and meta-analysis. Urol Oncol, 2020. 38: 344.
https://www.ncbi.nlm.nih.gov/pubmed/32192891
64.Dieckmann, K.P., et al. Carcinoma in situ of the testis: review of biological and clinical features. Int J Cancer, 1999. 83: 815.
https://www.ncbi.nlm.nih.gov/pubmed/10597201
65.Nason, G.J., et al. Partial orchiectomy: The Princess Margaret cancer centre experience. Urol Oncol, 2020. 38: 605 e19.
https://www.ncbi.nlm.nih.gov/pubmed/32284257
66.Fankhauser, C.D., et al. The Role of Frozen Section Examination During Inguinal Exploration in Men with Inconclusive Testicular Tumors: A Systematic Review and Meta-analysis. Eur Urol Focus, 2021. 7: 1400.
https://www.ncbi.nlm.nih.gov/pubmed/32684510
67.Bieniek, J.M., et al. Prevalence and Management of Incidental Small Testicular Masses Discovered on Ultrasonographic Evaluation of Male Infertility. J Urol, 2018. 199: 481.
https://www.ncbi.nlm.nih.gov/pubmed/28789946
68.Scandura, G., et al. Incidentally detected testicular lesions <10 mm in diameter: can orchidectomy be avoided? BJU Int, 2018. 121: 575.
https://www.ncbi.nlm.nih.gov/pubmed/29032579
69.Heidenreich, A., et al. Organ sparing surgery for malignant germ cell tumor of the testis. J Urol, 2001. 166: 2161.
https://pubmed.ncbi.nlm.nih.gov/11696727/
70.Paffenholz, P., et al. Testis Sparing Surgery for Benign Testicular Masses: Diagnostics and Therapeutic Approaches. J Urol, 2018. 200: 353.
https://pubmed.ncbi.nlm.nih.gov/29530784/
71.Grogg, J.B., et al. Oncological and functional outcomes after testis-sparing surgery in patients with germ cell tumors: a systematic review of 285 cases. World J Urol, 2022. 40: 2293.
https://www.ncbi.nlm.nih.gov/pubmed/35821265
72.Elert, A., et al. Accuracy of frozen section examination of testicular tumors of uncertain origin. Eur Urol, 2002. 41: 290.
https://pubmed.ncbi.nlm.nih.gov/12180230/
73.Skoogh, J., et al. Feelings of loss and uneasiness or shame after removal of a testicle by orchidectomy: a population-based long-term follow-up of testicular cancer survivors. Int J Androl, 2011. 34: 183.
https://www.ncbi.nlm.nih.gov/pubmed/20550599
74.Robinson, R., et al. Is it safe to insert a testicular prosthesis at the time of radical orchidectomy for testis cancer: an audit of 904 men undergoing radical orchidectomy. BJU Int, 2016. 117: 249.
https://www.ncbi.nlm.nih.gov/pubmed/25168859
75.Dieckmann, K.P., et al. Prevalence of contralateral testicular intraepithelial neoplasia in patients with testicular germ cell neoplasms. J Clin Oncol, 1996. 14: 3126.
https://www.ncbi.nlm.nih.gov/pubmed/8955658
76.Ruf, C.G., et al. Contralateral biopsies in patients with testicular germ cell tumours: patterns of care in Germany and recent data regarding prevalence and treatment of testicular intra-epithelial neoplasia. Andrology, 2015. 3: 92.
https://www.ncbi.nlm.nih.gov/pubmed/25146646
77.Andreassen, K.E., et al. Risk of metachronous contralateral testicular germ cell tumors: a population-based study of 7,102 Norwegian patients (1953-2007). Int J Cancer, 2011. 129: 2867.
https://www.ncbi.nlm.nih.gov/pubmed/21626506
78.Harland, S.J., et al. Intratubular germ cell neoplasia of the contralateral testis in testicular cancer: defining a high risk group. J Urol, 1998. 160: 1353.
https://www.ncbi.nlm.nih.gov/pubmed/9751353
79.Tabernero, J., et al. Incidence of contralateral germ cell testicular tumors in South Europe: report of the experience at 2 Spanish university hospitals and review of the literature. J Urol, 2004. 171: 164.
https://www.ncbi.nlm.nih.gov/pubmed/14665868
80.Albers, P., et al. Clinical course and histopathologic risk factor assessment in patients with bilateral testicular germ cell tumors. Urology, 1999. 54: 714.
https://www.ncbi.nlm.nih.gov/pubmed/10510934
81.Heidenreich, A., et al. Contralateral testicular biopsy procedure in patients with unilateral testis cancer: is it indicated? Semin Urol Oncol, 2002. 20: 234.
https://www.ncbi.nlm.nih.gov/pubmed/12489055
82.Giwercman, A., et al. Prevalence of carcinoma in situ and other histopathological abnormalities in testes of men with a history of cryptorchidism. J Urol, 1989. 142: 998.
https://www.ncbi.nlm.nih.gov/pubmed/2571738
83.Dieckmann, K.P., et al. Diagnosis of contralateral testicular intraepithelial neoplasia (TIN) in patients with testicular germ cell cancer: systematic two-site biopsies are more sensitive than a single random biopsy. Eur Urol, 2007. 51: 175.
https://www.ncbi.nlm.nih.gov/pubmed/16814456
84.Souchon, R., et al. Contralateral testicular cancer in spite of TIN-negative double biopsies and interval cisplatin chemotherapy. Strahlenther Onkol, 2006. 182: 289.
https://www.ncbi.nlm.nih.gov/pubmed/16673063
85.Hoei-Hansen, C.E., et al. Carcinoma in situ testis, the progenitor of testicular germ cell tumours: a clinical review. Ann Oncol, 2005. 16: 863.
https://www.ncbi.nlm.nih.gov/pubmed/15821122
86.Petersen, P.M., et al. Effect of graded testicular doses of radiotherapy in patients treated for carcinoma-in-situ in the testis. J Clin Oncol, 2002. 20: 1537.
https://www.ncbi.nlm.nih.gov/pubmed/11896102
87.Dieckmann, K.P., et al. Treatment of testicular intraepithelial neoplasia (intratubular germ cell neoplasia unspecified) with local radiotherapy or with platinum-based chemotherapy: a survey of the German Testicular Cancer Study Group. Ann Oncol, 2013. 24: 1332.
https://www.ncbi.nlm.nih.gov/pubmed/23293116
88.Classen, J., et al. Radiotherapy with 16 Gy may fail to eradicate testicular intraepithelial neoplasia: preliminary communication of a dose-reduction trial of the German Testicular Cancer Study Group. Br J Cancer, 2003. 88: 828.
https://www.ncbi.nlm.nih.gov/pubmed/12644817
89.Stephenson, A., et al. Diagnosis and Treatment of Early Stage Testicular Cancer: AUA Guideline. J Urol, 2019. 202: 272.
https://www.ncbi.nlm.nih.gov/pubmed/31059667
90.Christensen, T.B., et al. Effect of chemotherapy on carcinoma in situ of the testis. Ann Oncol, 1998. 9: 657.
https://www.ncbi.nlm.nih.gov/pubmed/9681081
91.Mortensen, M.S., et al. Treatment options for carcinoma in situ testis. Int J Androl, 2011. 34: e32.
https://www.ncbi.nlm.nih.gov/pubmed/21651575
92.Moch, H., et al., WHO Classification of Tumours of the Urinary System and Male Genital Organs. 4th ed. 2016, Lyon.
https://publications.iarc.who.int/Book-And-Report-Series/Who-Classification-Of-Tumours/WHO-Classification-Of-Tumours-Of-The-Urinary-System-And-Male-Genital-Organs-2016
93.Verrill, C., et al. Reporting and Staging of Testicular Germ Cell Tumors: The International Society of Urological Pathology (ISUP) Testicular Cancer Consultation Conference Recommendations. Am J Surg Pathol, 2017. 41: e22.
https://www.ncbi.nlm.nih.gov/pubmed/28368923
94.Verrill, C., et al. Intraoperative Consultation and Macroscopic Handling: The International Society of Urological Pathology (ISUP) Testicular Cancer Consultation Conference Recommendations. Am J Surg Pathol, 2018. 42: e33.
https://www.ncbi.nlm.nih.gov/pubmed/29579010
95.Berney, D.M., et al. Datasets for the reporting of neoplasia of the testis: recommendations from the International Collaboration on Cancer Reporting. Histopathology, 2019. 74: 171.
https://www.ncbi.nlm.nih.gov/pubmed/30565308
96.Force, U.S.P.S.T. Screening for testicular cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement. Ann Intern Med, 2011. 154: 483.
https://www.ncbi.nlm.nih.gov/pubmed/21464350
97.Ilic, D., et al. Screening for testicular cancer. Cochrane Database Syst Rev, 2011: CD007853.
https://www.ncbi.nlm.nih.gov/pubmed/21328302
98.Chong, R.I.H., et al. Testicular self-examination for early detection of testicular cancer. World J Urol, 2023. 41: 941.
https://www.ncbi.nlm.nih.gov/pubmed/37036497
99.Groll, R.J., et al. A comprehensive systematic review of testicular germ cell tumor surveillance. Crit Rev Oncol Hematol, 2007. 64: 182.
https://www.ncbi.nlm.nih.gov/pubmed/17644403
100.Nayan, M., et al. Conditional Risk of Relapse in Surveillance for Clinical Stage I Testicular Cancer. Eur Urol, 2017. 71: 120.
https://www.ncbi.nlm.nih.gov/pubmed/27527805
101.Tandstad, T., et al. Management of seminomatous testicular cancer: a binational prospective population-based study from the Swedish norwegian testicular cancer study group. J Clin Oncol, 2011. 29: 719.
https://www.ncbi.nlm.nih.gov/pubmed/21205748
102.Ruf, C.G., et al. Testicular germ cell tumours’ clinical stage I: comparison of surveillance with adjuvant treatment strategies regarding recurrence rates and overall survival-a systematic review. World J Urol, 2022. 40: 2889.
https://www.ncbi.nlm.nih.gov/pubmed/36107211
103.Chung, P., et al. Management of stage I seminomatous testicular cancer: a systematic review. Clin Oncol (R Coll Radiol), 2010. 22: 6.
https://www.ncbi.nlm.nih.gov/pubmed/19775876
104.Huang, M.M., et al. Cost-effectiveness Analysis of Non-risk-adapted Active Surveillance for Postorchiectomy Management of Clinical Stage I Seminoma. Eur Urol Focus, 2021. 7: 1409.
https://www.ncbi.nlm.nih.gov/pubmed/32646809
105.Oliver, R.T., et al. Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study (ISRCTN27163214). J Clin Oncol, 2011. 29: 957.
https://www.ncbi.nlm.nih.gov/pubmed/21282539
106.Aparicio, J., et al. Patterns of relapse and treatment outcome after active surveillance or adjuvant carboplatin for stage I seminoma: a retrospective study of the Spanish Germ Cell Cancer Group. Clin Transl Oncol, 2021. 23: 58.
https://www.ncbi.nlm.nih.gov/pubmed/32462393
107.Fischer, S., et al. Outcome of Men With Relapse After Adjuvant Carboplatin for Clinical Stage I Seminoma. J Clin Oncol, 2017. 35: 194.
https://www.ncbi.nlm.nih.gov/pubmed/27893332
108.Powles, T., et al. The long-term risks of adjuvant carboplatin treatment for stage I seminoma of the testis. Ann Oncol, 2008. 19: 443.
https://www.ncbi.nlm.nih.gov/pubmed/18048383
109.Bieri, S., et al. Seminoma of the testis: is scrotal shielding necessary when radiotherapy is limited to the para-aortic nodes? Radiother Oncol, 1999. 50: 349.
https://www.ncbi.nlm.nih.gov/pubmed/10392822
110.van den Belt-Dusebout, A.W., et al. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol, 2007. 25: 4370.
https://www.ncbi.nlm.nih.gov/pubmed/17906202
111.Horwich, A., et al. Second cancer risk and mortality in men treated with radiotherapy for stage I seminoma. Br J Cancer, 2014. 110: 256.
https://www.ncbi.nlm.nih.gov/pubmed/24263066
112.Patel, H.D., et al. Radiotherapy for stage I and II testicular seminomas: Secondary malignancies and survival. Urol Oncol, 2017. 35: 606 e1.
https://www.ncbi.nlm.nih.gov/pubmed/28712791
113.Tandstad, T., et al. Treatment of stage I seminoma, with one course of adjuvant carboplatin or surveillance, risk-adapted recommendations implementing patient autonomy: a report from the Swedish and Norwegian Testicular Cancer Group (SWENOTECA). Ann Oncol, 2016. 27: 1299.
https://www.ncbi.nlm.nih.gov/pubmed/27052649
114.Chung, P., et al. Evaluation of a prognostic model for risk of relapse in stage I seminoma surveillance. Cancer Med, 2015. 4: 155.
https://www.ncbi.nlm.nih.gov/pubmed/25236854
115.Mortensen, M.S., et al. A nationwide cohort study of stage I seminoma patients followed on a surveillance program. Eur Urol, 2014. 66: 1172.
https://www.ncbi.nlm.nih.gov/pubmed/25064686
116.Aparicio, J., et al. Prognostic factors for relapse in stage I seminoma: a new nomogram derived from three consecutive, risk-adapted studies from the Spanish Germ Cell Cancer Group (SGCCG). Ann Oncol, 2014. 25: 2173.
https://www.ncbi.nlm.nih.gov/pubmed/25210015
117.Kollmannsberger, C., et al. Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance. J Clin Oncol, 2015. 33: 51.
https://www.ncbi.nlm.nih.gov/pubmed/25135991
118.Hamilton, R.J., et al. Treatment of Relapse of Clinical Stage I Nonseminomatous Germ Cell Tumors on Surveillance. J Clin Oncol, 2019. 37: 1919.
https://www.ncbi.nlm.nih.gov/pubmed/30802156
119.Kollmannsberger, C., et al. Non-risk-adapted surveillance for patients with stage I nonseminomatous testicular germ-cell tumors: diminishing treatment-related morbidity while maintaining efficacy. Ann Oncol, 2010. 21: 1296.
https://www.ncbi.nlm.nih.gov/pubmed/19875756
120.Nichols, C.R., et al. Active surveillance is the preferred approach to clinical stage I testicular cancer. J Clin Oncol, 2013. 31: 3490.
https://www.ncbi.nlm.nih.gov/pubmed/24002502
121.Donohue, J.P., et al. Retroperitoneal lymphadenectomy for clinical stage A testis cancer (1965 to 1989): modifications of technique and impact on ejaculation. J Urol, 1993. 149: 237.
https://www.ncbi.nlm.nih.gov/pubmed/8381190
122.Nicolai, N., et al. Retroperitoneal lymph node dissection with no adjuvant chemotherapy in clinical stage I nonseminomatous germ cell tumours: long-term outcome and analysis of risk factors of recurrence. Eur Urol, 2010. 58: 912.
https://www.ncbi.nlm.nih.gov/pubmed/20817343
123.Nicolai, N., et al. Laparoscopic Retroperitoneal Lymph Node Dissection for Clinical Stage I Nonseminomatous Germ Cell Tumors of the Testis: Safety and Efficacy Analyses at a High Volume Center. J Urol, 2018. 199: 741.
https://www.ncbi.nlm.nih.gov/pubmed/28964782
124.Chavarriaga, J., et al. Long-term Relapse and Survival in Clinical Stage I Testicular Teratoma. Eur Urol Focus, 2025. 11: 258.
https://pubmed.ncbi.nlm.nih.gov/39455407/
125.Al-Ahmadie, H.A., et al. Primary retroperitoneal lymph node dissection in low-stage testicular germ cell tumors: a detailed pathologic study with clinical outcome analysis with special emphasis on patients who did not receive adjuvant therapy. Urology, 2013. 82: 1341.
https://www.ncbi.nlm.nih.gov/pubmed/24094656
126.Douglawi, A., et al. Long-Term Oncologic Outcomes after Primary Retroperitoneal Lymph Node Dissection: Minimizing the Need for Adjuvant Chemotherapy. J Urol, 2020. 204: 96.
https://www.ncbi.nlm.nih.gov/pubmed/32003612
127.Ghoreifi, A., et al. Re: Isamu Tachibana, Sean Q. Kern, Antoin Douglawi, et al. Primary Retroperitoneal Lymph Node Dissection for Patients with Pathologic Stage II Nonseminomatous Germ Cell Tumor-N1, N2, and N3 Disease: Is Adjuvant Chemotherapy Necessary? J Clin Oncol. In press.
https://pubmed.ncbi.nlm.nih.gov/35675585/
128.Heidenreich, A., et al. Complications of primary nerve sparing retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumors of the testis: experience of the German Testicular Cancer Study Group. J Urol, 2003. 169: 1710.
https://www.ncbi.nlm.nih.gov/pubmed/12686815
129.Albers, P., et al. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group. J Clin Oncol, 2008. 26: 2966.
https://www.ncbi.nlm.nih.gov/pubmed/18458040
130.Pearce, S.M., et al. Safety and Early Oncologic Effectiveness of Primary Robotic Retroperitoneal Lymph Node Dissection for Nonseminomatous Germ Cell Testicular Cancer. Eur Urol, 2017. 71: 476.
https://www.ncbi.nlm.nih.gov/pubmed/27234998
131.Calaway, A.C., et al. Adverse Surgical Outcomes Associated with Robotic Retroperitoneal Lymph Node Dissection Among Patients with Testicular Cancer. Eur Urol, 2019. 76: 607.
https://www.ncbi.nlm.nih.gov/pubmed/31174891
132.Rodrigues, G.J., et al. Robot-assisted retroperitoneal lymphadenectomy: The state of art. Asian J Urol, 2021. 8: 27.
https://www.ncbi.nlm.nih.gov/pubmed/33569270
133.Bhanvadia, R., et al. Population-based analysis of cost and peri-operative outcomes between open and robotic primary retroperitoneal lymph node dissection for germ cell tumors. World J Urol, 2021. 39: 1977.
https://www.ncbi.nlm.nih.gov/pubmed/32797261
134.Schermerhorn, S.M.V., et al. Learning Curve for Robotic-Assisted Laparoscopic Retroperitoneal Lymph Node Dissection. J Endourol, 2021. 35: 1483.
https://www.ncbi.nlm.nih.gov/pubmed/33559522
135.Supron, A.D., et al. Primary robotic retroperitoneal lymph node dissection following orchiectomy for testicular germ cell tumors: a single-surgeon experience. J Robot Surg, 2021. 15: 309.
https://www.ncbi.nlm.nih.gov/pubmed/32572754
136.Taylor, J., et al. Primary Robot-assisted Retroperitoneal Lymph Node Dissection for Men with Nonseminomatous Germ Cell Tumor: Experience from a Multi-institutional Cohort. Eur Urol Focus, 2021. 7: 1403.
https://www.ncbi.nlm.nih.gov/pubmed/32682794
137.Hiester, A., et al. Robotic Assisted Retroperitoneal Lymph Node Dissection for Small Volume Metastatic Testicular Cancer. J Urol, 2020. 204: 1242.
https://www.ncbi.nlm.nih.gov/pubmed/32717162
138.Pongratanakul, P., et al. Matched-pair analysis of peri-operative and oncological outcomes of robot-assisted vs open retroperitoneal lymph node dissection. BJU Int, 2025. 136: 150.
https://pubmed.ncbi.nlm.nih.gov/40260829/
139.Foster, R.S., et al. Clinical stage I nonseminoma: surgery versus surveillance. Semin Oncol, 1998. 25: 145.
https://www.ncbi.nlm.nih.gov/pubmed/9562447
140.Cullen, M.H., et al. Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report. J Clin Oncol, 1996. 14: 1106.
https://www.ncbi.nlm.nih.gov/pubmed/8648364
141.Pont, J., et al. Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: long-term results of a prospective trial. J Clin Oncol, 1996. 14: 441.
https://www.ncbi.nlm.nih.gov/pubmed/8636755
142.Chevreau, C., et al. Long-term efficacy of two cycles of BEP regimen in high-risk stage I nonseminomatous testicular germ cell tumors with embryonal carcinoma and/or vascular invasion. Eur Urol, 2004. 46: 209.
https://www.ncbi.nlm.nih.gov/pubmed/15245815
143.Bohlen, D., et al. Fertility and sexual function following orchiectomy and 2 cycles of chemotherapy for stage I high risk nonseminomatous germ cell cancer. J Urol, 2001. 165: 441.
https://www.ncbi.nlm.nih.gov/pubmed/11176393
144.Tandstad, T., et al. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program. J Clin Oncol, 2009. 27: 2122.
https://www.ncbi.nlm.nih.gov/pubmed/19307506
145.Tandstad, T., et al. One course of adjuvant BEP in clinical stage I nonseminoma mature and expanded results from the SWENOTECA group. Ann Oncol, 2014. 25: 2167.
https://www.ncbi.nlm.nih.gov/pubmed/25114021
146.Flechtner, H.H., et al. Quality-of-Life Analysis of the German Prospective Multicentre Trial of Single-cycle Adjuvant BEP Versus Retroperitoneal Lymph Node Dissection in Clinical Stage I Nonseminomatous Germ Cell Tumours. Eur Urol, 2016. 69: 518.
https://www.ncbi.nlm.nih.gov/pubmed/26620368
147.Huddart, R.A., et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol, 2003. 21: 1513.
https://www.ncbi.nlm.nih.gov/pubmed/12697875
148.Westermann, D.H., et al. Long-term followup results of 1 cycle of adjuvant bleomycin, etoposide and cisplatin chemotherapy for high risk clinical stage I nonseminomatous germ cell tumors of the testis. J Urol, 2008. 179: 163.
https://www.ncbi.nlm.nih.gov/pubmed/18001800
149.Fischer, S., et al. Outcome of Men With Relapses After Adjuvant Bleomycin, Etoposide, and Cisplatin for Clinical Stage I Nonseminoma. J Clin Oncol, 2020. 38: 1322.
https://www.ncbi.nlm.nih.gov/pubmed/31877087
150.Giannatempo, P., et al. Treatment and Clinical Outcomes of Patients with Teratoma with Somatic-Type Malignant Transformation: An International Collaboration. J Urol, 2016. 196: 95.
https://www.ncbi.nlm.nih.gov/pubmed/26748165
151.Hajiran, A., et al. Retroperitoneal Lymph Node Dissection Versus Surveillance for Adult Early Stage Pure Testicular Teratoma: A Nationwide Analysis. Ann Surg Oncol, 2021. 28: 3648.
https://www.ncbi.nlm.nih.gov/pubmed/33689081
152.Harari, S.E., et al. Testicular cancer: The usage of central review for pathology diagnosis of orchiectomy specimens. Urol Oncol, 2017. 35: 605 e9.
https://www.ncbi.nlm.nih.gov/pubmed/28647396
153.International Prognostic Factors Study, G., et al. Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. J Clin Oncol, 2010. 28: 4906.
https://www.ncbi.nlm.nih.gov/pubmed/20956623
154.Aparicio, J., et al. Treatment and Outcome of Patients with Stage IS Testicular Cancer: A Retrospective Study from the Spanish Germ Cell Cancer Group. J Urol, 2019. 202: 742.
https://www.ncbi.nlm.nih.gov/pubmed/31163007
155.Classen, J., et al. Radiotherapy for stages IIA/B testicular seminoma: final report of a prospective multicenter clinical trial. J Clin Oncol, 2003. 21: 1101.
https://www.ncbi.nlm.nih.gov/pubmed/12637477
156.Chung, P.W., et al. Stage II testicular seminoma: patterns of recurrence and outcome of treatment. Eur Urol, 2004. 45: 754.
https://www.ncbi.nlm.nih.gov/pubmed/15149748
157.Garcia-del-Muro, X., et al. Chemotherapy as an alternative to radiotherapy in the treatment of stage IIA and IIB testicular seminoma: a Spanish Germ Cell Cancer Group Study. J Clin Oncol, 2008. 26: 5416.
https://pubmed.ncbi.nlm.nih.gov/18936476/
158.Culine, S., et al. Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP). Ann Oncol, 2007. 18: 917.
https://www.ncbi.nlm.nih.gov/pubmed/17351252
159.Giannatempo, P., et al. Radiotherapy or chemotherapy for clinical stage IIA and IIB seminoma: a systematic review and meta-analysis of patient outcomes. Ann Oncol, 2015. 26: 657.
https://www.ncbi.nlm.nih.gov/pubmed/25214543
160.Heinzelbecker, J., et al. Therapy of clinical stage IIA and IIB seminoma: a systematic review. World J Urol, 2022. 40: 2829.
https://www.ncbi.nlm.nih.gov/pubmed/34779882
161.Hellesnes, R., et al. Continuing increased risk of second cancer in long-term testicular cancer survivors after treatment in the cisplatin era. Int J Cancer, 2020. 147: 21.
https://www.ncbi.nlm.nih.gov/pubmed/31597192
162.Hellesnes, R., et al. Testicular Cancer in the Cisplatin Era: Causes of Death and Mortality Rates in a Population-Based Cohort. J Clin Oncol, 2021. 39: 3561.
https://pubmed.ncbi.nlm.nih.gov/34388002/
163.Daneshmand, S., et al. Surgery in Early Metastatic Seminoma: A Phase II Trial of Retroperitoneal Lymph Node Dissection for Testicular Seminoma With Limited Retroperitoneal Lymphadenopathy. J Clin Oncol, 2023. 41: 3009.
https://www.ncbi.nlm.nih.gov/pubmed/36913642
164.Hiester, A., et al. Phase 2 Single-arm Trial of Primary Retroperitoneal Lymph Node Dissection in Patients with Seminomatous Testicular Germ Cell Tumors with Clinical Stage IIA/B (PRIMETEST). Eur Urol, 2023. 84: 25.
https://www.ncbi.nlm.nih.gov/pubmed/36372627
165.Heidenreich, A., et al. Retroperitoneal Lymph Node Dissection in Clinical Stage IIA/B Metastatic Seminoma: Results of the COlogne Trial of Retroperitoneal Lymphadenectomy In Metastatic Seminoma (COTRIMS). Eur Urol Oncol, 2024. 7: 122.
https://pubmed.ncbi.nlm.nih.gov/37438222/
166.Tachibana, I., et al. Primary Retroperitoneal Lymph Node Dissection for Stage II Seminoma: Is Surgery the New Path Forward? J Clin Oncol, 2023. 41: 3930.
https://www.ncbi.nlm.nih.gov/pubmed/36730902
167.Matulewicz, R.S., et al. Primary Retroperitoneal Lymph Node Dissection for Seminoma Metastatic to the Retroperitoneum. J Urol, 2023: 101097JU0000000000003697.
https://www.ncbi.nlm.nih.gov/pubmed/37672753
168.Thor, A., et al. Primary Retroperitoneal Lymph Node Dissection as Treatment for Low-volume Metastatic Seminoma in a Population-based Cohort: The Swedish Norwegian Testicular Cancer Group Experience. Eur Urol Open Sci, 2024. 65: 13.
https://pubmed.ncbi.nlm.nih.gov/38966804/
169.Loriot, Y., et al. The GETUG SEMITEP Trial: De-escalating Chemotherapy in Good-prognosis Seminoma Based on Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography. Eur Urol, 2022. 82: 172.
https://www.ncbi.nlm.nih.gov/pubmed/35599187
170.Papachristofilou, A., et al. Single-dose carboplatin followed by involved-node radiotherapy for stage IIA and stage IIB seminoma (SAKK 01/10): a single-arm, multicentre, phase 2 trial. Lancet Oncol, 2022. 23: 1441.
https://www.ncbi.nlm.nih.gov/pubmed/36228644
171.Neuenschwander, A., et al. Treatment Outcomes for Men with Clinical Stage II Nonseminomatous Germ Cell Tumours Treated with Primary Retroperitoneal Lymph Node Dissection: A Systematic Review. Eur Urol Focus, 2023. 9: 541.
https://www.ncbi.nlm.nih.gov/pubmed/36379869
172.Nicolai, N., et al. Retroperitoneal lymph-node dissection (RPLND) as upfront management in stage II germ-cell tumours: Evaluation of safety and efficacy. Tumori, 2023. 109: 379.
https://www.ncbi.nlm.nih.gov/pubmed/35915559
173.McHugh, D.J., et al. Adjuvant Chemotherapy With Etoposide Plus Cisplatin for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumors. J Clin Oncol, 2020. 38: 1332.
https://www.ncbi.nlm.nih.gov/pubmed/32109195
174.Stephenson, A.J., et al. Nonrandomized comparison of primary chemotherapy and retroperitoneal lymph node dissection for clinical stage IIA and IIB nonseminomatous germ cell testicular cancer. J Clin Oncol, 2007. 25: 5597.
https://www.ncbi.nlm.nih.gov/pubmed/18065732
175.Bokemeyer, C., et al. Metastatic seminoma treated with either single agent carboplatin or cisplatin-based combination chemotherapy: a pooled analysis of two randomised trials. Br J Cancer, 2004. 91: 683.
https://www.ncbi.nlm.nih.gov/pubmed/15266338
176.de Wit, R., et al. Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol, 1997. 15: 1837.
https://www.ncbi.nlm.nih.gov/pubmed/9164193
177.Patrikidou, A., et al. Redefining Good-prognosis Seminoma: Implications for Clinical Practice of the Updated International Germ Cell Cancer Collaborative Group Classification and Results from the SEMITrends Survey. Eur Urol Oncol, 2025. 8: 1248.
https://pubmed.ncbi.nlm.nih.gov/39915218/
178.de Wit, R., et al. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol, 2001. 19: 1629.
https://www.ncbi.nlm.nih.gov/pubmed/11250991
179.Fossa, S.D., et al. Quality of life in good prognosis patients with metastatic germ cell cancer: a prospective study of the European Organization for Research and Treatment of Cancer Genitourinary Group/Medical Research Council Testicular Cancer Study Group (30941/TE20). J Clin Oncol, 2003. 21: 1107.
https://www.ncbi.nlm.nih.gov/pubmed/12637478
180.Grimison, P.S., et al. Comparison of two standard chemotherapy regimens for good-prognosis germ cell tumors: updated analysis of a randomized trial. J Natl Cancer Inst, 2010. 102: 1253.
https://www.ncbi.nlm.nih.gov/pubmed/20631341
181.de Wit, R., et al. Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. European Organization for Research and Treatment of Cancer. Br J Cancer, 1998. 78: 828.
https://www.ncbi.nlm.nih.gov/pubmed/9743309
182.Nichols, C.R., et al. Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. J Clin Oncol, 1998. 16: 1287.
https://www.ncbi.nlm.nih.gov/pubmed/9552027
183.Daugaard, G., et al. A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974). Ann Oncol, 2011. 22: 1054.
https://www.ncbi.nlm.nih.gov/pubmed/21059637
184.Motzer, R.J., et al. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol, 2007. 25: 247.
https://www.ncbi.nlm.nih.gov/pubmed/17235042
185.Fizazi, K., et al. Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors. J Clin Oncol, 2004. 22: 3868.
https://www.ncbi.nlm.nih.gov/pubmed/15302906
186.Fizazi, K., et al. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial. Lancet Oncol, 2014. 15: 1442.
https://www.ncbi.nlm.nih.gov/pubmed/25456363
187.Bokemeyer, C., et al. Extragonadal germ cell tumors of the mediastinum and retroperitoneum: results from an international analysis. J Clin Oncol, 2002. 20: 1864.
https://www.ncbi.nlm.nih.gov/pubmed/11919246
188.Kollmannsberger, C., et al. Identification of prognostic subgroups among patients with metastatic ‘IGCCCG poor-prognosis’ germ-cell cancer: an explorative analysis using cart modeling. Ann Oncol, 2000. 11: 1115.
https://www.ncbi.nlm.nih.gov/pubmed/11061604
189.Winter, C., et al. How to classify, diagnose, treat and follow-up extragonadal germ cell tumors? A systematic review of available evidence. World J Urol, 2022. 40: 2863.
https://www.ncbi.nlm.nih.gov/pubmed/35554637
190.Bokemeyer, C., et al. First-line sequential high-dose VIP chemotherapy with autologous transplantation for patients with primary mediastinal nonseminomatous germ cell tumours: a prospective trial. Br J Cancer, 2003. 89: 29.
https://www.ncbi.nlm.nih.gov/pubmed/12838296
191.Collette, L., et al. Impact of the treating institution on survival of patients with “poor-prognosis” metastatic nonseminoma. European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group and the Medical Research Council Testicular Cancer Working Party. J Natl Cancer Inst, 1999. 91: 839.
https://www.ncbi.nlm.nih.gov/pubmed/10340903
192.Massard, C., et al. Poor prognosis nonseminomatous germ-cell tumours (NSGCTs): should chemotherapy doses be reduced at first cycle to prevent acute respiratory distress syndrome in patients with multiple lung metastases? Ann Oncol, 2010. 21: 1585.
https://www.ncbi.nlm.nih.gov/pubmed/20181575
193.Woldu, S.L., et al. Impact of hospital case volume on testicular cancer outcomes and practice patterns. Urol Oncol, 2018. 36: 14 e7.
https://www.ncbi.nlm.nih.gov/pubmed/28935185
194.Gillessen, S., et al. Low-dose induction chemotherapy with Baby-BOP in patients with metastatic germ-cell tumours does not compromise outcome: a single-centre experience. Ann Oncol, 2010. 21: 1589.
https://www.ncbi.nlm.nih.gov/pubmed/20164149
195.Khorana, A.A., et al. Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer. N Engl J Med, 2019. 380: 720.
https://www.ncbi.nlm.nih.gov/pubmed/30786186
196.Carrier, M., et al. Apixaban to Prevent Venous Thromboembolism in Patients with Cancer. N Engl J Med, 2019. 380: 711.
https://www.ncbi.nlm.nih.gov/pubmed/30511879
197.Agnelli, G., et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med, 2012. 366: 601.
https://www.ncbi.nlm.nih.gov/pubmed/22335737
198.Agnelli, G., et al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol, 2009. 10: 943.
https://www.ncbi.nlm.nih.gov/pubmed/19726226
199.Key, N.S., et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol, 2020. 38: 496.
https://www.ncbi.nlm.nih.gov/pubmed/31381464
200.Gizzi, M., et al. Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemotherapy for germ cell tumours. Eur J Cancer, 2016. 69: 151.
https://www.ncbi.nlm.nih.gov/pubmed/27821318
201.Fankhauser, C.D., et al. A Risk-benefit Analysis of Prophylactic Anticoagulation for Patients with Metastatic Germ Cell Tumours Undergoing First-line Chemotherapy. Eur Urol Focus, 2021. 7: 1130.
https://www.ncbi.nlm.nih.gov/pubmed/33032968
202.Haugnes, H.S., et al. Thromboembolic Events During Treatment with Cisplatin-based Chemotherapy in Metastatic Testicular Germ-cell Cancer 2000-2014: A Population-based Cohort Study. Eur Urol Open Sci, 2021. 32: 19.
https://www.ncbi.nlm.nih.gov/pubmed/34667955
203.Andre, F., et al. The growing teratoma syndrome: results of therapy and long-term follow-up of 33 patients. Eur J Cancer, 2000. 36: 1389.
https://www.ncbi.nlm.nih.gov/pubmed/10899652
204.Che, Y., et al. Late relapsing germ cell tumors with elevated tumor markers. World J Urol, 2022. 40: 363.
https://www.ncbi.nlm.nih.gov/pubmed/34518930
205.Fossa, S.D., et al. Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours. Br J Cancer, 1999. 80: 1392.
https://www.ncbi.nlm.nih.gov/pubmed/10424741
206.Hofmockel, G., et al. Chemotherapy in advanced seminoma and the role of postcytostatic retroperitoneal lymph node dissection. Urol Int, 1996. 57: 38.
https://www.ncbi.nlm.nih.gov/pubmed/8840489
207.Kamat, M.R., et al. Value of retroperitoneal lymph node dissection in advanced testicular seminoma. J Surg Oncol, 1992. 51: 65.
https://www.ncbi.nlm.nih.gov/pubmed/1381455
208.Motzer, R., et al. Residual mass: an indication for further therapy in patients with advanced seminoma following systemic chemotherapy. J Clin Oncol, 1987. 5: 1064.
https://www.ncbi.nlm.nih.gov/pubmed/3598610
209.De Santis, M., et al. 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J Clin Oncol, 2004. 22: 1034.
https://www.ncbi.nlm.nih.gov/pubmed/15020605
210.Bachner, M., et al. 2-(1)(8)fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial. Ann Oncol, 2012. 23: 59.
https://www.ncbi.nlm.nih.gov/pubmed/21460378
211.Beyer, J., et al. Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann Oncol, 2013. 24: 878.
https://www.ncbi.nlm.nih.gov/pubmed/23152360
212.Oechsle, K., et al. [18F]Fluorodeoxyglucose positron emission tomography in nonseminomatous germ cell tumors after chemotherapy: the German multicenter positron emission tomography study group. J Clin Oncol, 2008. 26: 5930.
https://www.ncbi.nlm.nih.gov/pubmed/19018083
213.Cathomas, R., et al. Questioning the Value of Fluorodeoxyglucose Positron Emission Tomography for Residual Lesions After Chemotherapy for Metastatic Seminoma: Results of an International Global Germ Cell Cancer Group Registry. J Clin Oncol, 2018. 36: JCO1800210.
https://www.ncbi.nlm.nih.gov/pubmed/30285559
214.Herr, H.W., et al. Surgery for a post-chemotherapy residual mass in seminoma. J Urol, 1997. 157: 860.
https://www.ncbi.nlm.nih.gov/pubmed/9072586
215.Mosharafa, A.A., et al. Is post-chemotherapy resection of seminomatous elements associated with higher acute morbidity? J Urol, 2003. 169: 2126.
https://www.ncbi.nlm.nih.gov/pubmed/12771733
216.Puc, H.S., et al. Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center. J Clin Oncol, 1996. 14: 454.
https://www.ncbi.nlm.nih.gov/pubmed/8636757
217.Conduit, C., et al. A meta-analysis of clinicopathologic features that predict necrosis or fibrosis at post-chemotherapy retroperitoneal lymph node dissection in individuals receiving treatment for non-seminoma germ cell tumours. Front Oncol, 2022. 12: 931509.
https://www.ncbi.nlm.nih.gov/pubmed/36059636
218.Nason, G.J., et al. Long-term Surveillance of Patients with Complete Response Following Chemotherapy for Metastatic Nonseminomatous Germ Cell Tumor. Eur Urol Oncol, 2021. 4: 289.
https://www.ncbi.nlm.nih.gov/pubmed/32907779
219.Ehrlich, Y., et al. Long-term follow-up of Cisplatin combination chemotherapy in patients with disseminated nonseminomatous germ cell tumors: is a postchemotherapy retroperitoneal lymph node dissection needed after complete remission? J Clin Oncol, 2010. 28: 531.
https://www.ncbi.nlm.nih.gov/pubmed/20026808
220.Hartmann, J.T., et al. Comparison of histological results from the resection of residual masses at different sites after chemotherapy for metastatic non-seminomatous germ cell tumours. Eur J Cancer, 1997. 33: 843.
https://www.ncbi.nlm.nih.gov/pubmed/9291803
221.Hendry, W.F., et al. Metastatic nonseminomatous germ cell tumors of the testis: results of elective and salvage surgery for patients with residual retroperitoneal masses. Cancer, 2002. 94: 1668.
https://www.ncbi.nlm.nih.gov/pubmed/11920527
222.Sheinfeld, J. The role of adjunctive postchemotherapy surgery for nonseminomatous germ-cell tumors: current concepts and controversies. Semin Urol Oncol, 2002. 20: 262.
https://www.ncbi.nlm.nih.gov/pubmed/12489059
223.Steyerberg, E.W., et al. Prediction models for the histology of residual masses after chemotherapy for metastatic testicular cancer. ReHiT Study Group. Int J Cancer, 1999. 83: 856.
https://www.ncbi.nlm.nih.gov/pubmed/10597211
224.Oldenburg, J., et al. Postchemotherapy retroperitoneal surgery remains necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses. J Clin Oncol, 2003. 21: 3310.
https://www.ncbi.nlm.nih.gov/pubmed/12947067
225.Antonelli, L., et al. Risk of residual cancer after complete response following first-line chemotherapy in men with metastatic non-seminomatous germ cell tumour and International Germ Cell Cancer Cooperative Group intermediate/poor prognosis: A multi-institutional retrospective cohort study. Eur J Cancer, 2023. 182: 144.
https://www.ncbi.nlm.nih.gov/pubmed/36787661
226.Rick, O., et al. Residual tumor resection after high-dose chemotherapy in patients with relapsed or refractory germ cell cancer. J Clin Oncol, 2004. 22: 3713.
https://www.ncbi.nlm.nih.gov/pubmed/15365067
227.Heidenreich, A., et al. Postchemotherapy retroperitoneal lymph node dissection in advanced testicular cancer: radical or modified template resection. Eur Urol, 2009. 55: 217.
https://www.ncbi.nlm.nih.gov/pubmed/18926622
228.Gerdtsson, A., et al. Unilateral or Bilateral Retroperitoneal Lymph Node Dissection in Nonseminoma Patients with Postchemotherapy Residual Tumour? Results from RETROP, a Population-based Mapping Study by the Swedish Norwegian Testicular Cancer Group. Eur Urol Oncol, 2022. 5: 235.
https://www.ncbi.nlm.nih.gov/pubmed/33750683
229.Beck, S.D., et al. Is full bilateral retroperitoneal lymph node dissection always necessary for postchemotherapy residual tumor? Cancer, 2007. 110: 1235.
https://www.ncbi.nlm.nih.gov/pubmed/17665498
230.Large, M.C., et al. Retroperitoneal lymph node dissection: reassessment of modified templates. BJU Int, 2009. 104: 1369.
https://www.ncbi.nlm.nih.gov/pubmed/19840015
231.Carver, B.S., et al. Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma. J Clin Oncol, 2007. 25: 1033.
https://www.ncbi.nlm.nih.gov/pubmed/17261854
232.Fizazi, K., et al. Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international study. Ann Oncol, 2008. 19: 259.
https://www.ncbi.nlm.nih.gov/pubmed/18042838
233.Busch, J., et al. Laparoscopic and open postchemotherapy retroperitoneal lymph node dissection in patients with advanced testicular cancer--a single center analysis. BMC Urol, 2012. 12: 15.
https://www.ncbi.nlm.nih.gov/pubmed/22651395
234.Arai, Y., et al. Extraperitoneal laparoscopic retroperitoneal lymph node dissection after chemotherapy for nonseminomatous testicular germ-cell tumor: surgical and oncological outcomes. Int Urol Nephrol, 2012. 44: 1389.
https://www.ncbi.nlm.nih.gov/pubmed/22648291
235.Nicolai, N., et al. Laparoscopic Postchemotherapy Retroperitoneal Lymph-Node Dissection Can Be a Standard Option in Defined Nonseminomatous Germ Cell Tumor Patients. J Endourol, 2016. 30: 1112.
https://www.ncbi.nlm.nih.gov/pubmed/27533924
236.Fankhauser, C.D., et al. Minimally invasive retroperitoneal lymph node dissection for men with testis cancer: a retrospective cohort study of safety and feasibility. World J Urol, 2022. 40: 1505.
https://www.ncbi.nlm.nih.gov/pubmed/35279732
237.Steyerberg, E.W., et al. Residual masses after chemotherapy for metastatic testicular cancer: the clinical implications of the association between retroperitoneal and pulmonary histology. Re-analysis of Histology in Testicular Cancer (ReHiT) Study Group. J Urol, 1997. 158: 474.
https://www.ncbi.nlm.nih.gov/pubmed/9224327
238.Besse, B., et al. Nonseminomatous germ cell tumors: assessing the need for postchemotherapy contralateral pulmonary resection in patients with ipsilateral complete necrosis. J Thorac Cardiovasc Surg, 2009. 137: 448.
https://www.ncbi.nlm.nih.gov/pubmed/19185168
239.Schirren, J., et al. The role of residual tumor resection in the management of nonseminomatous germ cell cancer of testicular origin. Thorac Cardiovasc Surg, 2012. 60: 405.
https://www.ncbi.nlm.nih.gov/pubmed/22383152
240.Ehrlich, Y., et al. Vena caval reconstruction during postchemotherapy retroperitoneal lymph node dissection for metastatic germ cell tumor. Urology, 2009. 73: 442 e17.
https://www.ncbi.nlm.nih.gov/pubmed/18436290
241.Heidenreich, A., et al. Surgical management of complex residual masses following systemic chemotherapy for metastatic testicular germ cell tumours. Ann Oncol, 2017. 28: 362.
https://www.ncbi.nlm.nih.gov/pubmed/27831507
242.Winter, C., et al. Residual tumor size and IGCCCG risk classification predict additional vascular procedures in patients with germ cell tumors and residual tumor resection: a multicenter analysis of the German Testicular Cancer Study Group. Eur Urol, 2012. 61: 403.
https://www.ncbi.nlm.nih.gov/pubmed/22078334
243.Wells, H., et al. Contemporary retroperitoneal lymph node dissection (RPLND) for testis cancer in the UK - a national study. BJU Int, 2017. 119: 91.
https://www.ncbi.nlm.nih.gov/pubmed/27353395
244.Capitanio, U., et al. Population-based study of perioperative mortality after retroperitoneal lymphadenectomy for nonseminomatous testicular germ cell tumors. Urology, 2009. 74: 373.
https://www.ncbi.nlm.nih.gov/pubmed/19501893
245.Flechon, A., et al. Long-term oncological outcome after post-chemotherapy retroperitoneal lymph node dissection in men with metastatic nonseminomatous germ cell tumour. BJU Int, 2010. 106: 779.
https://www.ncbi.nlm.nih.gov/pubmed/20089110
246.Eggener, S.E., et al. Pathologic findings and clinical outcome of patients undergoing retroperitoneal lymph node dissection after multiple chemotherapy regimens for metastatic testicular germ cell tumors. Cancer, 2007. 109: 528.
https://www.ncbi.nlm.nih.gov/pubmed/17177200
247.Oechsle, K., et al. Long-term survival after treatment with gemcitabine and oxaliplatin with and without paclitaxel plus secondary surgery in patients with cisplatin-refractory and/or multiply relapsed germ cell tumors. Eur Urol, 2011. 60: 850.
https://www.ncbi.nlm.nih.gov/pubmed/21704446
248.Nicolai, N., et al. Long-term results of a combination of paclitaxel, cisplatin and gemcitabine for salvage therapy in male germ-cell tumours. BJU Int, 2009. 104: 340.
https://www.ncbi.nlm.nih.gov/pubmed/19239440
249.Beck, S.D., et al. Outcome analysis for patients with elevated serum tumor markers at postchemotherapy retroperitoneal lymph node dissection. J Clin Oncol, 2005. 23: 6149.
https://www.ncbi.nlm.nih.gov/pubmed/16135481
250.Fizazi, K., et al. Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy--results from an international study group. J Clin Oncol, 2001. 19: 2647.
https://www.ncbi.nlm.nih.gov/pubmed/11352956
251.Antonelli, L., et al. Risk Factors for Relapse in Nonseminomatous Testicular Cancer After Postchemotherapy Retroperitoneal Lymph Node Dissection With Viable Residual Cancer. J Clin Oncol, 2023: JCO2300443.
https://www.ncbi.nlm.nih.gov/pubmed/37656935
252.Miller, K.D., et al. Salvage chemotherapy with vinblastine, ifosfamide, and cisplatin in recurrent seminoma. J Clin Oncol, 1997. 15: 1427.
https://www.ncbi.nlm.nih.gov/pubmed/9193335
253.Fizazi, K., et al. Combining gemcitabine, cisplatin, and ifosfamide (GIP) is active in patients with relapsed metastatic germ-cell tumors (GCT): a prospective multicenter GETUG phase II trial. Ann Oncol, 2014. 25: 987.
https://www.ncbi.nlm.nih.gov/pubmed/24595454
254.Mead, G.M., et al. A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second-line (post-BEP) salvage chemotherapy for patients with metastatic germ cell cancer: a medical research council trial. Br J Cancer, 2005. 93: 178.
https://www.ncbi.nlm.nih.gov/pubmed/15999102
255.Lorch, A., et al. Sequential versus single high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: long-term results of a prospective randomized trial. J Clin Oncol, 2012. 30: 800.
https://www.ncbi.nlm.nih.gov/pubmed/22291076
256.Oechsle, K., et al. Patterns of relapse after chemotherapy in patients with high-risk non-seminomatous germ cell tumor. Oncology, 2010. 78: 47.
https://www.ncbi.nlm.nih.gov/pubmed/20215785
257.Agarwala, A.K., et al. Salvage chemotherapy with high-dose carboplatin and etoposide with peripheral blood stem cell transplant in patients with relapsed pure seminoma. Am J Clin Oncol, 2011. 34: 286.
https://www.ncbi.nlm.nih.gov/pubmed/20523207
258.Berger, L.A., et al. First salvage treatment in patients with advanced germ cell cancer after cisplatin-based chemotherapy: analysis of a registry of the German Testicular Cancer Study Group (GTCSG). J Cancer Res Clin Oncol, 2014. 140: 1211.
https://www.ncbi.nlm.nih.gov/pubmed/24696231
259.Massard, C., et al. Tumor marker kinetics predict outcome in patients with relapsed disseminated non-seminomatous germ-cell tumors. Ann Oncol, 2013. 24: 322.
https://www.ncbi.nlm.nih.gov/pubmed/23104726
260.Necchi, A., et al. Prognostic impact of progression to induction chemotherapy and prior paclitaxel therapy in patients with germ cell tumors receiving salvage high-dose chemotherapy in the last 10 years: a study of the European Society for Blood and Marrow Transplantation Solid Tumors Working Party. Bone Marrow Transplant, 2016. 51: 384.
https://www.ncbi.nlm.nih.gov/pubmed/26642334
261.Bin Riaz, I., et al. Role of one, two and three doses of high-dose chemotherapy with autologous transplantation in the treatment of high-risk or relapsed testicular cancer: a systematic review. Bone Marrow Transplant, 2018. 53: 1242.
https://www.ncbi.nlm.nih.gov/pubmed/29703969
262.Taza, F., et al. Maintenance Oral Etoposide After High-Dose Chemotherapy (HDCT) for Patients With Relapsed Metastatic Germ-Cell Tumors (mGCT). Clin Genitourin Cancer, 2023. 21: 213.
https://www.ncbi.nlm.nih.gov/pubmed/36737276
263.Necchi, A., et al. Combination of paclitaxel, cisplatin, and gemcitabine (TPG) for multiple relapses or platinum-resistant germ cell tumors: long-term outcomes. Clin Genitourin Cancer, 2014. 12: 63.
https://www.ncbi.nlm.nih.gov/pubmed/24161525
264.Mulherin, B.P., et al. Long-term survival with paclitaxel and gemcitabine for germ cell tumors after progression following high-dose chemotherapy with tandem transplant. Am J Clin Oncol, 2015. 38: 373.
https://www.ncbi.nlm.nih.gov/pubmed/26214082
265.Lorch, A., et al. Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study Group. J Clin Oncol, 2007. 25: 2778.
https://www.ncbi.nlm.nih.gov/pubmed/17602082
266.Jay, A.P.M., et al. Features and Management of Late Relapse of Nonseminomatous Germ Cell Tumour. Eur Urol Open Sci, 2021. 29: 82.
https://www.ncbi.nlm.nih.gov/pubmed/34337537
267.Oldenburg, J., et al. Late relapses of germ cell malignancies: incidence, management, and prognosis. J Clin Oncol, 2006. 24: 5503.
https://www.ncbi.nlm.nih.gov/pubmed/17158535
268.Oldenburg, J., et al. Late recurrences of germ cell malignancies: a population-based experience over three decades. Br J Cancer, 2006. 94: 820.
https://www.ncbi.nlm.nih.gov/pubmed/16508636
269.Richardson, N.H., et al. Late Relapse of Germ Cell Tumors After Prior Chemotherapy or Surgery-only. Clin Genitourin Cancer, 2023. 21: 467.
https://www.ncbi.nlm.nih.gov/pubmed/37088659
270.Baniel, J., et al. Late relapse of testicular cancer. J Clin Oncol, 1995. 13: 1170.
https://www.ncbi.nlm.nih.gov/pubmed/7537800
271.George, D.W., et al. Update on late relapse of germ cell tumor: a clinical and molecular analysis. J Clin Oncol, 2003. 21: 113.
https://www.ncbi.nlm.nih.gov/pubmed/12506179
272.Alifrangis, C., et al. Management of Late Relapses After Chemotherapy in Testicular Cancer: Optimal Outcomes with Dose-intense Salvage Chemotherapy and Surgery. Eur Urol Focus, 2021. 7: 835.
https://www.ncbi.nlm.nih.gov/pubmed/32381397
273.Moore, J.A., et al. Very Late Recurrence in Germ Cell Tumor of the Testis: Lessons and Implications. Cancers (Basel), 2022. 14: 1127.
https://www.ncbi.nlm.nih.gov/pubmed/35267435
274.Lee, A.H., et al. The value of central histopathological review of testicular tumours before treatment. BJU Int, 1999. 84: 75.
https://www.ncbi.nlm.nih.gov/pubmed/10444128
275.Lipphardt, M.E., et al. Late relapse of testicular cancer. World J Urol, 2004. 22: 47.
https://www.ncbi.nlm.nih.gov/pubmed/15064970
276.Fossa, S.D., et al. Treatment outcome of patients with brain metastases from malignant germ cell tumors. Cancer, 1999. 85: 988.
https://www.ncbi.nlm.nih.gov/pubmed/10091779
277.Bokemeyer, C., et al. Treatment of brain metastases in patients with testicular cancer. J Clin Oncol, 1997. 15: 1449.
https://www.ncbi.nlm.nih.gov/pubmed/9193339
278.Hartmann JT, et al. Multidiciplinary treatment and prognosis of patients with central nervous metastases (CNS) from testicular germ cell tumour (GCT) origin. Proc Ann Soc Clin Oncol, 2003. 22.
https://www.sciencedirect.com/science/article/pii/S1359634903908755
279.Casey, D.L., et al. High-dose radiation therapy is needed for intracranial control and long-term survival in patients with non-seminomatous germ cell tumor brain metastases. J Neurooncol, 2019. 142: 523.
https://pubmed.ncbi.nlm.nih.gov/30771201/
280.Group., I.G.C.C.C. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol, 1997. 15: 594.
https://pubmed.ncbi.nlm.nih.gov/9053482/
281.Oing, C., et al. First salvage treatment of germ cell tumor patients with bone metastases: retrospective analysis of a large international database. J Cancer Res Clin Oncol, 2015. 141: 923.
https://pubmed.ncbi.nlm.nih.gov/25395217/
282.Engst, R., et al. Interim results of studies of microbial isomerization of gamma-hexachlorocyclohexane. Bull Environ Contam Toxicol, 1979. 22: 699.
https://pubmed.ncbi.nlm.nih.gov/90534/
283.Oechsle, K., et al. Bone metastases in germ cell tumor patients. J Cancer Res Clin Oncol, 2012. 138: 947.
https://pubmed.ncbi.nlm.nih.gov/22350540/
284.Oing, C., et al. Impact of primary metastatic bone disease in germ cell tumors: results of an International Global Germ Cell Tumor Collaborative Group G3 Registry Study. Ann Oncol, 2017. 28: 576.
https://pubmed.ncbi.nlm.nih.gov/27993806/
285.Honecker, F., et al. ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up. Ann Oncol, 2018. 29: 1658.
https://www.ncbi.nlm.nih.gov/pubmed/30113631
286.Hale, G.R., et al. Lymph node imaging in testicular cancer. Transl Androl Urol, 2018. 7: 864.
https://www.ncbi.nlm.nih.gov/pubmed/30456189
287.Joffe, J.K., et al. Imaging Modality and Frequency in Surveillance of Stage I Seminoma Testicular Cancer: Results From a Randomized, Phase III, Noninferiority Trial (TRISST). J Clin Oncol, 2022. 40: 2468.
https://www.ncbi.nlm.nih.gov/pubmed/35298280
288.Thomas, K.L., et al. The role of diagnostic imaging in the primary testicular cancer: initial staging, response assessment and surveillance. Transl Androl Urol, 2020. 9: S3.
https://www.ncbi.nlm.nih.gov/pubmed/32055480
289.Sohaib, S.A., et al. Prospective assessment of MRI for imaging retroperitoneal metastases from testicular germ cell tumours. Clin Radiol, 2009. 64: 362.
https://www.ncbi.nlm.nih.gov/pubmed/19264179
290.Laukka, M., et al. Comparison between CT and MRI in detection of metastasis of the retroperitoneum in testicular germ cell tumors: a prospective trial. Acta Oncol, 2020. 59: 660.
https://www.ncbi.nlm.nih.gov/pubmed/32048533
291.Loughrey, G.J., et al. The value of specialist oncological radiology review of cross-sectional imaging. Clin Radiol, 1999. 54: 149.
https://www.ncbi.nlm.nih.gov/pubmed/10201861
292.Larsen, S.K.A., et al. Ten years of experience with MRI follow-up of testicular cancer stage I: a retrospective study and an MRI protocol with DWI. Acta Oncol, 2020. 59: 1374.
https://www.ncbi.nlm.nih.gov/pubmed/32684054
293.Conduit, C., et al. Two decades of FDG-PET/CT in seminoma: exploring its role in diagnosis, surveillance and follow-up. Cancer Imaging, 2022. 22: 58.
https://www.ncbi.nlm.nih.gov/pubmed/36209121
294.Fischer, S., et al. The Value of Tumour Markers in the Detection of Relapse-Lessons Learned from the Swiss Austrian German Testicular Cancer Cohort Study. Eur Urol Open Sci, 2023. 50: 57.
https://www.ncbi.nlm.nih.gov/pubmed/36874175
295.Kaufmann, E., et al. Oncological Follow-up Strategies for Testicular Germ Cell Tumours: A Narrative Review. Eur Urol Open Sci, 2022. 44: 142.
https://www.ncbi.nlm.nih.gov/pubmed/36106144
296.Mortensen, M.S., et al. Late Relapses in Stage I Testicular Cancer Patients on Surveillance. Eur Urol, 2016. 70: 365.
https://www.ncbi.nlm.nih.gov/pubmed/26996661
297.Travis, L.B., et al. Testicular cancer survivorship: research strategies and recommendations. J Natl Cancer Inst, 2010. 102: 1114.
https://www.ncbi.nlm.nih.gov/pubmed/20585105
298.Agrawal, V., et al. Adverse Health Outcomes Among US Testicular Cancer Survivors After Cisplatin-Based Chemotherapy vs Surgical Management. JNCI Cancer Spectr, 2020. 4: pkz079.
https://www.ncbi.nlm.nih.gov/pubmed/32190815
299.Kerns, S.L., et al. Relationship of Cisplatin-Related Adverse Health Outcomes With Disability and Unemployment Among Testicular Cancer Survivors. JNCI Cancer Spectr, 2020. 4: pkaa022.
https://www.ncbi.nlm.nih.gov/pubmed/32704617
300.Haugnes, H.S., et al. Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up. J Clin Oncol, 2012. 30: 3752.
https://www.ncbi.nlm.nih.gov/pubmed/23008318
301.Alberti, K.G., et al. The metabolic syndrome--a new worldwide definition. Lancet, 2005. 366: 1059.
https://www.ncbi.nlm.nih.gov/pubmed/16182882
302.Giannoulatou, E., et al. Whole-genome sequencing of spermatocytic tumors provides insights into the mutational processes operating in the male germline. PLoS One, 2017. 12: e0178169.
https://www.ncbi.nlm.nih.gov/pubmed/28542371
303.Moch, H., et al. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. Eur Urol, 2016. 70: 93.
https://www.ncbi.nlm.nih.gov/pubmed/26935559
304.Grogg, J.B., et al. A systematic review of treatment outcomes in localised and metastatic spermatocytic tumors of the testis. J Cancer Res Clin Oncol, 2019. 145: 3037.
https://www.ncbi.nlm.nih.gov/pubmed/31646373
305.Idrees, M.T., et al. The World Health Organization 2016 classification of testicular non-germ cell tumours: a review and update from the International Society of Urological Pathology Testis Consultation Panel. Histopathology, 2017. 70: 513.
https://www.ncbi.nlm.nih.gov/pubmed/27801954
306.Nicolai, N., et al. Clinical outcome in testicular sex cord stromal tumors: testis sparing vs. radical orchiectomy and management of advanced disease. Urology, 2015. 85: 402.
https://pubmed.ncbi.nlm.nih.gov/25623702/
307.Corcioni, B., et al. Multiparametric ultrasound for the diagnosis of Leydig cell tumours in non-palpable testicular lesions. Andrology, 2022. 10: 1387.
https://www.ncbi.nlm.nih.gov/pubmed/35842907
308.Ruf, C.G., et al. Leydig-cell tumour of the testis: retrospective analysis of clinical and therapeutic features in 204 cases. World J Urol, 2020. 38: 2857.
https://www.ncbi.nlm.nih.gov/pubmed/31960106
309.Fankhauser, C.D., et al. Risk Factors and Treatment Outcomes of 1,375 Patients with Testicular Leydig Cell Tumors: Analysis of Published Case Series Data. J Urol, 2020. 203: 949.
https://www.ncbi.nlm.nih.gov/pubmed/31845841
310.Colecchia, M., et al. The Leydig cell tumour Scaled Score (LeSS): a method to distinguish benign from malignant cases, with additional correlation with MDM2 and CDK4 amplification. Histopathology, 2021. 78: 290.
https://pubmed.ncbi.nlm.nih.gov/32757426/
311.Cheville, J.C., et al. Leydig cell tumor of the testis: a clinicopathologic, DNA content, and MIB-1 comparison of nonmetastasizing and metastasizing tumors. Am J Surg Pathol, 1998. 22: 1361.
https://pubmed.ncbi.nlm.nih.gov/9808128/
312.Grogg, J., et al. Sertoli Cell Tumors of the Testes: Systematic Literature Review and Meta-Analysis of Outcomes in 435 Patients. Oncologist, 2020. 25: 585.
https://www.ncbi.nlm.nih.gov/pubmed/32043680
313.Grogg, J.B., et al. Risk factors and treatment outcomes of 239 patients with testicular granulosa cell tumors: a systematic review of published case series data. J Cancer Res Clin Oncol, 2020. 146: 2829.
https://www.ncbi.nlm.nih.gov/pubmed/32719989
314.Cornejo, K.M., et al. Adult granulosa cell tumors of the testis: a report of 32 cases. Am J Surg Pathol, 2014. 38: 1242.
https://pubmed.ncbi.nlm.nih.gov/24705318/
315.Zhang, M., et al. Testicular fibrothecoma: a morphologic and immunohistochemical study of 16 cases. Am J Surg Pathol, 2013. 37: 1208.
https://www.ncbi.nlm.nih.gov/pubmed/23715159
316.Bhambhvani, H.P., et al. Primary malignancies of the epididymis: clinical characteristics and prognostic factors. Can J Urol, 2021. 28: 10522.
https://www.ncbi.nlm.nih.gov/pubmed/33625342
317.Chowdhry, V.K., et al. Testicular, Spermatic Cord, and Scrotal Soft Tissue Sarcomas: Treatment Outcomes and Patterns of Failure. Sarcoma, 2021. 2021: 8824301.
https://www.ncbi.nlm.nih.gov/pubmed/33746565
318.Radaelli, S., et al. Prognostic factors and outcome of spermatic cord sarcoma. Ann Surg Oncol, 2014. 21: 3557.
https://www.ncbi.nlm.nih.gov/pubmed/24802908
319.Bharti, J.N., et al. Cytomorphological spectrum of epididymal nodules: An institution’s experience. Cytojournal, 2017. 14: 26.
https://www.ncbi.nlm.nih.gov/pubmed/29259652
320.Tsili, A.C., et al. MRI of the scrotum: Recommendations of the ESUR Scrotal and Penile Imaging Working Group. Eur Radiol, 2018. 28: 31.
https://www.ncbi.nlm.nih.gov/pubmed/28698942
321.Grogg, J.B., et al. Clinicopathological characteristics and outcomes in men with mesothelioma of the tunica vaginalis testis: analysis of published case-series data. J Cancer Res Clin Oncol, 2021. 147: 2671.
https://www.ncbi.nlm.nih.gov/pubmed/33559739
322.Fankhauser, C.D., et al. Treatment and follow-up of rare testis tumours. J Cancer Res Clin Oncol, 2022. 148: 667.
https://www.ncbi.nlm.nih.gov/pubmed/35048196